(Q58849503)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

main subject

metastatic breast cancer

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Patrizia Vici

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Mirella Marino

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Stefania Gori

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Roberta Merola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Gianluigi Ferretti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Anna Di Benedetto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Barbara Antoniani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Cristiana Ercolani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Cecilia Nisticò

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Paola Papaldo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Mariangela Ciccarese

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Claudio Botti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Paola Malaguti

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Francesco Cognetti

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Marcella Mottolese

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Alessandra Fabi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

9 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

699-706

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

EGFR expression and gene copy number in triple-negative breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779672

10.1517/14656566.2013.779672

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23472669%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference